Protagonist Therapeutics (PTGX) Change in Accured Expenses (2015 - 2026)

Protagonist Therapeutics has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$10.8 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$10.8 million, up 8.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (up 220.24% YoY), and the FY2025 annual result was $4.6 million, up 6.69% from the prior year.
• Change in Accured Expenses came in at -$10.8 million for Q1 2026 at Protagonist Therapeutics, down from $5.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q3 2025 to a low of -$11.8 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is -$1.4 million (2024), against an average of -$1.2 million.
• Across the five-year window, Change in Accured Expenses tumbled 659.29% in 2022 and soared 353.05% in 2025, its largest moves.
• Protagonist Therapeutics' Change in Accured Expenses stood at -$4.6 million in 2022, then declined by 16.35% to -$5.3 million in 2023, then jumped by 160.47% to $3.2 million in 2024, then soared by 67.57% to $5.4 million in 2025, then tumbled by 299.52% to -$10.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$10.8 million (Q1 2026), $5.4 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.